Streptococcus pneumoniae continues to be a common cause of pneumonia, bacteremia, acute otitis media (AOM), and sinusitis. This pathogen causes about 40,000 deaths annually in the United States. The 23-valent pneumococcal polysaccharide vaccine effectively prevents S pneumoniae infection in many patient populations, but it is not recommended for children younger than 2 years - a group that has a particularly high incidence of invasive pneumococcal disease. Recently, a heptavalent pneumococcal conjugate vaccine (PCV) was approved for infants and toddlers, beginning at 2 months of age. This vaccine contains the 7 serotypes that account for most cases of invasive pneumococcal disease and AOM in US children and has an efficacy rate of 97% against invasive disease caused by these serotypes. The PCV has demonstrated an excellent safety profile, with no significant adverse effects.
|Original language||English (US)|
|Number of pages||9|
|Journal||Journal of Respiratory Diseases|
|State||Published - Jan 1 2000|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine